Teva CEO sees minimal impact from potential U.S. tariffs despite ’big ambiguity’ in sector

Published 30/07/2025, 15:14
© Reuters.

Investing.com -- Teva Pharmaceutical (TADAWUL:2070) Industries (NYSE:TEVA) CEO Richard Francis said on Wednesday the company is well-positioned to handle potential U.S. tariffs despite "big ambiguity" in the drugs sector regarding these measures.

Francis noted that 70% of Teva’s generics business operates outside the United States, while most of its branded drugs business is within the U.S. The company’s largest drug, Huntington’s Disease treatment Austedo, is manufactured in the United States.

Following Teva’s second-quarter earnings release, Francis highlighted the company’s favorable supply chain structure, which includes no reliance on China and very little dependence on India. "Those aspects just set us up in the face of this change, probably a lot better than our competitors," he said.

The CEO expressed confidence in Teva’s position while acknowledging remaining uncertainties, stating, "I feel we have the ability to put ourselves in a good position here, with the caveat - I need to know the details."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.